ASX - By Stock
|
AGN |
Re:
Ann: Argenica Successfully Completes $12.0m Placement
|
|
Werble
|
58 |
13K |
5 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
58
|
13K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Ann: US patent allowed for CHM 0201 (CORE-NK) technology
|
|
Werble
|
15 |
5.2K |
0 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
15
|
5.2K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
Werble
|
48 |
14K |
1 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
48
|
14K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
Werble
|
48 |
14K |
2 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
48
|
14K
|
2
|
|
ASX - By Stock
|
TLX |
Re:
TLX Chart
|
|
Werble
|
1.5K |
563K |
3 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
1.5K
|
563K
|
3
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
Werble
|
759 |
343K |
3 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
759
|
343K
|
3
|
|
ASX - By Stock
|
TLX |
Re:
TLX Chart
|
|
Werble
|
1.5K |
563K |
2 |
16/03/24 |
16/03/24 |
ASX - By Stock
|
1.5K
|
563K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
Werble
|
48 |
14K |
7 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
48
|
14K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
Werble
|
48 |
14K |
2 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
48
|
14K
|
2
|
|
ASX - By Stock
|
PER |
Re:
per-chart
|
|
Werble
|
626 |
145K |
6 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
626
|
145K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
Werble
|
39 |
8.3K |
2 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
8.3K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
Werble
|
39 |
8.3K |
5 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
8.3K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
Werble
|
39 |
8.3K |
0 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
39
|
8.3K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
[INTERVIEW] Recce Pharmaceuticals secures AUD$11.18M from Endpoints Capital
|
|
Werble
|
3 |
753 |
4 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
3
|
753
|
4
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Corporate Presentation
|
|
Werble
|
118 |
23K |
1 |
10/03/24 |
10/03/24 |
ASX - By Stock
|
118
|
23K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Dimerix (ASX: DXB) Discussion Thread
|
|
Werble
|
629 |
201K |
16 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
629
|
201K
|
16
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Continues Strategic Partnership with MCRI
|
|
Werble
|
53 |
14K |
1 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
53
|
14K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Continues Strategic Partnership with MCRI
|
|
Werble
|
53 |
14K |
3 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
53
|
14K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Continues Strategic Partnership with MCRI
|
|
Werble
|
53 |
14K |
4 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
53
|
14K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
DXB Chart
|
|
Werble
|
811 |
278K |
4 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
811
|
278K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Werble
|
692 |
275K |
3 |
02/03/24 |
02/03/24 |
ASX - By Stock
|
692
|
275K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Chimeric to present at ********* Hidden Gems webinar
|
|
Werble
|
17 |
5.4K |
8 |
02/03/24 |
02/03/24 |
ASX - By Stock
|
17
|
5.4K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Chimeric to present at ********* Hidden Gems webinar
|
|
Werble
|
17 |
5.4K |
6 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
17
|
5.4K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Continues Strategic Partnership with MCRI
|
|
Werble
|
53 |
14K |
7 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
53
|
14K
|
7
|
|
ASX - By Stock
|
TLX |
Re:
Ann: 2023 Full Year Results Presentation
|
|
Werble
|
30 |
10K |
4 |
23/02/24 |
23/02/24 |
ASX - By Stock
|
30
|
10K
|
4
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix 2023 Full Year Results and Investor Webcast/Call
|
|
Werble
|
130 |
42K |
1 |
23/02/24 |
23/02/24 |
ASX - By Stock
|
130
|
42K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix 2023 Full Year Results and Investor Webcast/Call
|
|
Werble
|
130 |
42K |
3 |
23/02/24 |
23/02/24 |
ASX - By Stock
|
130
|
42K
|
3
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix 2023 Full Year Results and Investor Webcast/Call
|
|
Werble
|
130 |
42K |
4 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
130
|
42K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Application for quotation of securities - DXB
|
|
Werble
|
34 |
10K |
4 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
34
|
10K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Werble
|
34 |
10K |
1 |
02/02/24 |
02/02/24 |
ASX - By Stock
|
34
|
10K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
TLX Chart
|
|
Werble
|
1.5K |
563K |
3 |
02/02/24 |
02/02/24 |
ASX - By Stock
|
1.5K
|
563K
|
3
|
|
ASX - By Stock
|
TLX |
Re:
AFR - Why $3b Aussie darling Telix needs to grow wings
|
|
Werble
|
17 |
8.8K |
6 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
17
|
8.8K
|
6
|
|
ASX - By Stock
|
TLX |
Re:
AFR - Why $3b Aussie darling Telix needs to grow wings
|
|
Werble
|
17 |
8.8K |
1 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
17
|
8.8K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix Plans U.S. Registered Public Offering and Listing
|
|
Werble
|
45 |
18K |
3 |
06/01/24 |
06/01/24 |
ASX - By Stock
|
45
|
18K
|
3
|
|
ASX - By Stock
|
TLX |
Re:
TLX Chart
|
|
Werble
|
1.5K |
563K |
1 |
21/12/23 |
21/12/23 |
ASX - By Stock
|
1.5K
|
563K
|
1
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
Werble
|
759 |
343K |
5 |
20/12/23 |
20/12/23 |
ASX - By Stock
|
759
|
343K
|
5
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix Submits BLA for TLX250-CDx for Kidney Cancer Imaging
|
|
Werble
|
44 |
14K |
2 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
44
|
14K
|
2
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Update on Financial Reporting Requirements
|
|
Werble
|
14 |
4.0K |
3 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
14
|
4.0K
|
3
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Update on Financial Reporting Requirements
|
|
Werble
|
14 |
4.0K |
2 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
14
|
4.0K
|
2
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Update on Financial Reporting Requirements
|
|
Werble
|
14 |
4.0K |
2 |
18/12/23 |
18/12/23 |
ASX - By Stock
|
14
|
4.0K
|
2
|
|
ASX - By Stock
|
TLX |
Re:
TLX Chart
|
|
Werble
|
1.5K |
563K |
6 |
15/12/23 |
15/12/23 |
ASX - By Stock
|
1.5K
|
563K
|
6
|
|
ASX - By Stock
|
TLX |
Re:
TLX Chart
|
|
Werble
|
1.5K |
563K |
5 |
11/12/23 |
11/12/23 |
ASX - By Stock
|
1.5K
|
563K
|
5
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
Werble
|
759 |
343K |
4 |
06/12/23 |
06/12/23 |
ASX - By Stock
|
759
|
343K
|
4
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
Werble
|
759 |
343K |
6 |
02/12/23 |
02/12/23 |
ASX - By Stock
|
759
|
343K
|
6
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
Werble
|
759 |
343K |
2 |
23/11/23 |
23/11/23 |
ASX - By Stock
|
759
|
343K
|
2
|
|
ASX - By Stock
|
TLX |
Re:
CB presenting at Jefferies London this Thursday (3am)
|
|
Werble
|
17 |
5.1K |
2 |
17/11/23 |
17/11/23 |
ASX - By Stock
|
17
|
5.1K
|
2
|
|
ASX - By Stock
|
TLX |
Re:
CB presenting at Jefferies London this Thursday (3am)
|
|
Werble
|
17 |
5.1K |
3 |
16/11/23 |
16/11/23 |
ASX - By Stock
|
17
|
5.1K
|
3
|
|
ASX - By Stock
|
TLX |
Re:
CB presenting at Jefferies London this Thursday (3am)
|
|
Werble
|
17 |
5.1K |
9 |
16/11/23 |
16/11/23 |
ASX - By Stock
|
17
|
5.1K
|
9
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix Announces Proposed Acquisition of QSAM Biosciences
|
|
Werble
|
24 |
8.7K |
6 |
14/11/23 |
14/11/23 |
ASX - By Stock
|
24
|
8.7K
|
6
|
|
ASX - By Stock
|
TLX |
CB presenting at Jefferies London this Thursday (3am)
|
|
Werble
|
17 |
5.1K |
2 |
14/11/23 |
14/11/23 |
ASX - By Stock
|
17
|
5.1K
|
2
|
|